• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Enovis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    12/10/25 6:30:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    false 0001420800 0001420800 2025-12-08 2025-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 8, 2025

     

     

     

    Enovis Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-34045   54-1887631
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)

     

    2711 Centerville Road, Suite 400

    Wilmington, DE 19808

    (Address of principal executive offices) (Zip Code)

     

    (302) 252-9160

    (Registrant’s telephone number, including area code)

     

    Not applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   ENOV   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On December 8, 2025, Enovis Corporation, a Delaware corporation (the “Company”), entered into Amendment No. 3 (the “Third Amendment”) to the Credit Agreement, dated April 4, 2022 (as amended by Amendment No. 1 to Credit Agreement, dated October 23, 2023 and Amendment No. 2 to Credit Agreement, dated March 28, 2024, the “Existing Credit Agreement,” and the Existing Credit Agreement, as amended by the Third Amendment, the “Amended Credit Agreement”), by and among the Company, certain subsidiaries of the Company identified therein as guarantors, each of the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent.

     

    The Amended Credit Agreement provides for a revolving credit facility of up to $1.1 billion (the “Revolving Facility” and the loans thereunder, the “Revolving Loans”) and a term loan facility of $700.0 million (the “Term Loan Facility” and the loans thereunder, the “Term Loans”). The Third Amendment extended the maturity date for all outstanding Revolving Loans and Term Loans to December 8, 2030 (the “Maturity Date”); provided, however, that in the event that 91 days prior to such Maturity Date, the Company’s liquidity (calculated as set forth in the Amended Credit Agreement, based on the Company’s and its subsidiaries’ unrestricted, unencumbered and freely transferrable cash and cash equivalents, plus the aggregate amount of available unused revolving commitments under the Revolving Facility) is less than 125% of the then-outstanding principal balance of the Company’s senior unsecured convertible notes, then all outstanding Revolving Loans and Term Loans will mature on the date that is 91 days prior to the Maturity Date.

     

    Consistent with the Existing Credit Agreement, the Amended Credit Agreement provides that the Company must maintain a Senior Secured Leverage Ratio (as defined in the Amended Credit Agreement) of at least 3.50 to 1.00, but provides for a temporary increase in the maximum Senior Secured Leverage Ratio threshold, at the election of the Company and subject to certain conditions, following one or more acquisitions for which the aggregate consideration is $300.0 million or more. Under the Existing Credit Agreement, such temporary increase in the maximum Senior Secured Leverage Ratio threshold was available following one or more acquisitions for which the aggregate consideration was $500.0 million or more. The Third Amendment also increased the maximum amount of unrestricted, unencumbered and freely transferrable cash and cash equivalents that may be applied to offset the amount of indebtedness used in the calculations of the Senior Secured Leverage Ratio and the Total Leverage Ratio (as defined in the Amended Credit Agreement). Pursuant to the Amended Credit Agreement, the amount of indebtedness used in such calculations may be reduced by up to $400.0 million of the Company’s and its subsidiaries’ unrestricted, unencumbered and freely transferrable cash and cash equivalents, compared to $150.0 million under the Existing Credit Agreement. Further, the Third Amendment (i) reduced the applicable margin for borrowings if the Total Leverage Ratio (as defined in the Amended Credit Agreement) is less than 1.50 to 1.00 and (ii) modified certain negative covenants to increase the maximum consideration payable for a permitted acquisition from $150.0 million to $200.0 million and increased baskets available for additional debt.

     

    In addition, in connection with the Third Amendment, each of Truist Bank, DNB Capital LLC and Sumitomo Mitsui Banking Corporation became a lender under the Amended Credit Agreement.

     

    A portion of the proceeds from the Term Loan Facility was used to repay approximately $335.0 million of the outstanding principal balance under the Revolving Facility. Accordingly, as of December 8, 2025, after giving effect to the Third Amendment, $167.0 million of principal was outstanding under the Revolving Facility and $700.0 million of principal was outstanding under the Term Loan Facility.

     

    The lenders that are parties to the Amended Credit Agreement and their respective affiliates are full-service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage, and other financial and non-financial activities and services. Certain of these financial institutions and their respective affiliates have provided, and may in the future provide, certain of these services to the Company and its subsidiaries and to persons and entities with relationships with the Company and its subsidiaries, for which they received or will receive customary fees and expenses.

     

    The foregoing description of the Third Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Third Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

     

     

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    10.1#   Amendment No. 3 to Credit Agreement, dated as of December 8, 2025, by and among the Company, the lenders and guarantors party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent.
    104   Cover Page Interactive Data File - The cover page from this Current Report on Form 8-K is formatted in Inline XBRL.

     

    #   Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish to the Securities and Exchange Commission a copy of any omitted schedule or exhibit upon request.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 10, 2025    
         
      ENOVIS CORPORATION
         
      By:

    /s/ Bradley J. Tandy

      Name: Bradley J. Tandy
      Title: Senior Vice President and Chief Legal Officer

     

     

    Get the next $ENOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Kleckner John bought $74,830 worth of shares (2,468 units at $30.32), increasing direct ownership by 25% to 12,302 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    11/28/25 4:30:09 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Director Lalor Angela S was granted 742 shares, increasing direct ownership by 4% to 21,295 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    10/1/25 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Executive Officer Mcdonald Damien bought $199,973 worth of shares (6,457 units at $30.97), increasing direct ownership by 7% to 102,753 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    9/11/25 5:59:16 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on Enovis Corporation with a new price target

    JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

    10/3/24 7:29:21 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JP Morgan initiated coverage on Enovis Corporation with a new price target

    JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

    6/13/24 7:06:52 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Stephens initiated coverage on Enovis Corporation with a new price target

    Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00

    2/13/24 6:34:49 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enovis Announces Third Quarter 2025 Results

    Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus

    11/6/25 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

    Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com. Additionally, the company also announced it will participate in the following investor conferences: UBS Global Healthcare Conference: Damien McD

    10/24/25 4:11:14 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million

    Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones. "This transaction represents a positive outcome for Enovis, our Dr. Comfort business, and Promus Equity Partners," said Damien McDonald, Enovis' Chief Executive Officer. "The sale sharpens our fo

    10/8/25 8:15:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Kleckner John bought $74,830 worth of shares (2,468 units at $30.32), increasing direct ownership by 25% to 12,302 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    11/28/25 4:30:09 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Executive Officer Mcdonald Damien bought $199,973 worth of shares (6,457 units at $30.97), increasing direct ownership by 7% to 102,753 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    9/11/25 5:59:16 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SVP and Chief Legal Officer Tandy Bradley J bought $100,512 worth of shares (3,200 units at $31.41), increasing direct ownership by 8% to 43,515 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/25/25 6:30:04 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    SEC Filings

    View All

    Enovis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Enovis CORP (0001420800) (Filer)

    12/10/25 6:30:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Corporation filed SEC Form 8-K: Leadership Update

    8-K - Enovis CORP (0001420800) (Filer)

    11/14/25 4:05:37 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Enovis Corporation

    10-Q - Enovis CORP (0001420800) (Filer)

    11/6/25 6:25:16 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Enovis Announces Third Quarter 2025 Results

    Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus

    11/6/25 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

    Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com. Additionally, the company also announced it will participate in the following investor conferences: UBS Global Healthcare Conference: Damien McD

    10/24/25 4:11:14 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Second Quarter 2025 Results

    Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter

    8/7/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

    WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le

    9/9/24 3:50:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care